特应性皮炎（AD）前沿文献精读特辑（Dermatol Ther (Heidelb)）
深度精选：乌帕替尼治疗中重度特应性皮炎的52周累积疾病控制：IL-AD多中心真实 等 1 篇重磅文献
系统精读发表于 Dermatol Ther (Heidelb) 等顶刊的特应性皮炎最新重磅研究：涵盖 临床研究型、基础研究型 等前沿维度，解析核心靶点、循证数据与一线转化启示。
【特应性皮炎前沿快报】 本期精选今日全球顶尖医学期刊发表的重磅特应性皮炎（AD）研究成果。涵盖基础免疫病理与临床靶向治疗前沿，助力把握 AD 疾病生物学与个体化诊疗脉搏。
📑 本期文献快速导航
- 1. 《Dermatol Ther (Heidelb)》乌帕替尼治疗中重度特应性皮炎的52周累积疾病控制：IL-AD多中心真实世界队列研究
真实世界与队列· 核心靶点：乌帕替尼（Upadacitinib）为高选择性JAK1抑制剂，通过特异性阻断JAK1-ST…
1. 《Dermatol Ther (Heidelb)》乌帕替尼治疗中重度特应性皮炎的52周累积疾病控制：IL-AD多中心真实世界队列研究
英文原题: Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis-A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
发表期刊: Dermatology and therapy (Dermatol Ther (Heidelb)) | 影响因子: 3.9 (3区)
文献检索: PubMed: 42879117 · DOI: 10.1007/s13555-026-01958-w
研究分类: 真实世界与队列 | 标签: #真实世界与队列 #特应性皮炎 #JAK1 #乌帕替尼 #累积疾病控制 #Dermatol Ther (Heidelb)
📌 核心定论 / Core Conclusion
这项纳入433例中重度AD患者的52周多中心真实世界研究证实，固定剂量乌帕替尼可诱导并维持长期高水平临床应答。研究首次引入“目标控制时间内（time-in-target）”动态评估维度，证实患者在52周随访期内平均分别获得253.3天和176.1天的中度与最佳疾病控制时间，有效突破了传统离散时间点终点对长期疾病控制连续性评估的局限。
🔬 研究方法与样本 / Design
多中心回顾性真实世界注册队列研究（基于前瞻性收集的LANDSCAPE队列数据），样本量 N=433
🎯 机制与靶点 / Mechanism & Target
乌帕替尼（Upadacitinib）为高选择性JAK1抑制剂，通过特异性阻断JAK1-STAT胞内信号通路，强效下调下游IL-4、IL-13、IL-31及TSLP等多重2型炎症与瘙痒关键细胞因子的传导。
📊 核心数据与关键发现
- 第52周皮损与双重达标率：EASI-75与EASI-90应答率分别达85.7%和72.7%；中度疾病控制（EASI-75且pp-NRS≤4）与最佳疾病控制/微小疾病活动度MDA（EASI-90且pp-NRS≤1）达成率分别为80.6%和62.6%
- 动态累积获益时间（Time-in-Target）：在52周（365天）观察期内，患者平均处于中度疾病控制状态为253.3±101.9天，处于最佳控制/MDA状态为176.1±124.4天
- 长期持续缓解率：自第16周至第52周维持无中断中度疾病控制与最佳疾病控制/MDA的患者比例分别为63.0%和38.3%
- 安全性与药物留存：总AE发生率为27.0%，随访期内无因不良事件导致永久停药的病例，体现了良好的真实世界耐受性
💡 专家深度评析与转化启示
特应性皮炎作为一种高复发性、病程波动的慢性系统性炎症性疾病，传统临床试验基于静态横截面（如W16/W52单时间点）的评价模式难以真实反映患者全病程的“疾病无发作/低负担累积天数”。本研究引入的“目标控制时间（Time-in-Target）”理念，为AD乃至整个炎症性皮肤病领域提供了与糖尿病“血糖在目标范围内时间（TIR）”类似的疾病综合控制范式，高度契合“完全清除+迅速且持续止痒”的双重达标（Treat-to-Target, T2T）前沿策略。 从一线处方决策来看，无论采用15 mg还是30 mg固定维持剂量，乌帕替尼均在真实世界多中心队列中展现出极佳的长期药物留存率与累积控制时间。这为中重度AD患者在生物制剂应答不佳或追求高黏性、长期深层缓解（EASI-90 + pp-NRS≤1）场景下的口服JAK1抑制剂长期维持治疗提供了坚实的循证医学依据。
展开查看英文原始摘要 (Original Abstract)
INTRODUCTION: Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control. METHODS: This multicenter retrospective analysis of prospectively collected LANDSCAPE registry data included patients with moderate-to-severe AD receiving stable upadacitinib 15 mg or 30 mg once daily. Patients who underwent dose modification from 15 to 30 mg or from 30 to 15 mg during the 52-week observation period were excluded from the present analysis to ensure that longitudinal outcomes and cumulative disease-control estimates could be consistently attributed to a stable upadacitinib dose. Outcomes were assessed at baseline and weeks 16, 32, and 52. Moderate disease control was defined as EASI75 plus peak pruritus numerical rating scale (pp-NRS) ≤ 4, and optimal disease control/minimal disease activity (MDA) as EASI90 plus pp-NRS ≤ 1. Cumulative control was estimated as equivalent days in target using a time-in-target approach. RESULTS: Overall, 433 patients were included; 315 (72.7%) received 15 mg and 118 (27.3%) received 30 mg. At week 52, EASI75 and EASI90 were achieved by 85.7% and 72.7% of patients, respectively; moderate and optimal disease control/MDA were achieved by 80.6% and 62.6%. Patients spent a mean of 253.3 ± 101.9 equivalent days in moderate disease control and 176.1 ± 124.4 days in optimal control/MDA. Sustained moderate and optimal disease control from weeks 16 to 52 were achieved by 63.0% and 38.3%, respectively. Overall, 27.0% experienced at least one adverse event, with no permanent treatment discontinuations due to adverse events. CONCLUSION: Upadacitinib provided sustained real-world disease control over 52 weeks. Time-in-target measures may complement conventional endpoints by better reflecting persistence of therapeutic benefit.